Cargando…
Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults
BACKGROUND: DNA vaccines are a promising approach to vaccination since they circumvent the problem of vector-induced immunity. DNA plasmid cytokine adjuvants have been shown to augment immune responses in small animals and in macaques. METHODOLOGY/PRINCIPAL FINDINGS: We performed two first in human...
Autores principales: | Kalams, Spyros A., Parker, Scott, Jin, Xia, Elizaga, Marnie, Metch, Barbara, Wang, Maggie, Hural, John, Lubeck, Michael, Eldridge, John, Cardinali, Massimo, Blattner, William A., Sobieszczyk, Magda, Suriyanon, Vinai, Kalichman, Artur, Weiner, David B., Baden, Lindsey R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252307/ https://www.ncbi.nlm.nih.gov/pubmed/22242162 http://dx.doi.org/10.1371/journal.pone.0029231 |
Ejemplares similares
-
Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial
por: Elizaga, Marnie L., et al.
Publicado: (2018) -
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP(®) DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults
por: Edupuganti, Srilatha, et al.
Publicado: (2020) -
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)
por: Fuchs, Jonathan D., et al.
Publicado: (2015) -
HIV-exposed uninfected infants: elevated cord blood Interleukin 8 (IL-8) is significantly associated with maternal HIV infection and systemic IL-8 in a Kenyan cohort
por: Lohman-Payne, Barbara, et al.
Publicado: (2018) -
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
por: Mayer, Kenneth H., et al.
Publicado: (2017)